Ozge Nur Aktaş1, Ayşe Bilge Öztürk2, Baran Erman3, Suat Erus4, Serhan Tanju4, Şükrü Dilege4. 1. Feinberg School of Medicine, Center for Community Health, Northwestern University, Chicago, IL, USA. 2. Department of Allergy and Immunology, Koç University Hospital, Istanbul, Turkey. aysebilgeozturk@yahoo.com. 3. Koç University, School of Medicine, Translational Medicine Research Center, Istanbul, Turkey. 4. Department of Thoracic Surgery, Koç University Hospital, Istanbul, Turkey.
Abstract
PURPOSE: One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival. METHODS: The relevant literature from PubMed and Medline databases is reviewed in this article. RESULTS: The cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival. CONCLUSIONS: The NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.
PURPOSE: One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival. METHODS: The relevant literature from PubMed and Medline databases is reviewed in this article. RESULTS: The cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival. CONCLUSIONS: The NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.
Entities:
Keywords:
Immunotherapy; Lung cancer; Natural killer cells; Non-small cell lung cancer; Small cell lung cancer
Authors: Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet Journal: Adv Immunol Date: 2014 Impact factor: 3.543
Authors: Rizwan Romee; Bree Foley; Todd Lenvik; Yue Wang; Bin Zhang; Dave Ankarlo; Xianghua Luo; Sarah Cooley; Mike Verneris; Bruce Walcheck; Jeffrey Miller Journal: Blood Date: 2013-03-13 Impact factor: 22.113
Authors: Fei Li; Qingyuan Huang; Troy A Luster; Hai Hu; Hua Zhang; Wai-Lung Ng; Alireza Khodadadi-Jamayran; Wei Wang; Ting Chen; Jiehui Deng; Michela Ranieri; Zhaoyuan Fang; Val Pyon; Catríona M Dowling; Ece Bagdatlioglu; Christina Almonte; Kristen Labbe; Heather Silver; Alexandra R Rabin; Kandarp Jani; Aristotelis Tsirigos; Thales Papagiannakopoulos; Peter S Hammerman; Vamsidhar Velcheti; Gordon J Freeman; Jun Qi; George Miller; Kwok-Kin Wong Journal: Cancer Discov Date: 2019-11-19 Impact factor: 38.272
Authors: Clara Degos; Mellie Heinemann; Julien Barrou; Nicolas Boucherit; Eric Lambaudie; Ariel Savina; Laurent Gorvel; Daniel Olive Journal: Front Immunol Date: 2019-04-26 Impact factor: 7.561